Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7366283 | 0.75 | CYP2A6 (0.33) | — | |
| SCHEMBL5455704 | 0.74 | — | — | |
| SCHEMBL15056035 | 0.73 | GABRA1 (0.33) | GABRA1GABRB2ALOX5PTGS1PTGS2 | |
| SCHEMBL4591842 | 0.73 | GABRA1 (0.38) | GABRA1GABRB2ALOX5PTGS1PTGS2 | |
| SCHEMBL1383883 | 0.72 | GABRA1 (0.32) | GABRA1GABRB2 | |
| SCHEMBL1164626 | 0.71 | GABRA1 (0.36) | GABRA1GABRB2ALOX5PTGS1PTGS2 | |
| SCHEMBL13572315 | 0.69 | — | — | |
| SCHEMBL2882496 | 0.69 | — | — | |
| SCHEMBL6036916 | 0.69 | — | — | |
| SCHEMBL4677442 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217824-B2 | Process for preparing a 4,7-bis(5-halothien-2-yl)-2,1,3-benzothiadiazole and a precursor therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-15 | — | — | US | claimed |
| US-20040229925-A1 | Process for preparing a 4,7-bis(5-halothien-2-yl)-2,1,3-benzothiadiazole and a precursor therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-18 | — | — | US | claimed |
| WO-2014074027-A1 | POLYMERS AND THEIR USE IN PHOTOVOLTAIC DEVICES | LANXESS DEUTSCHLAND GMBH (DE) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014074028-A2 | POLYMERS AND THEIR USE IN PHOTOVOLTAIC DEVICES | INSTITUTE OF PROBLEMS OF CHEMICAL PHYSICS RAS (RU) | 2014-05-15 | — | — | WO | disclosed |
| EP-2730633-A1 | Polymer compound and its use in photovoltaic devices | LANXESS Deutschland GmbH (DE) | 2014-05-14 | — | — | EP | disclosed |
| EP-2730632-A1 | Polymer compound and its use in photovoltaic devices | LANXESS Deutschland GmbH (DE) | 2014-05-14 | — | — | EP | disclosed |
| EP-2730600-A1 | Conjugated polymer compound comprising 1,2,3-Benzothiadiazole units and its use in photovoltaic devices | LANXESS Deutschland GmbH (DE) | 2014-05-14 | — | — | EP | disclosed |
| US-8558108-B2 | Electron donating material, material for photovoltaic devices and photovoltaic device | TORAY INDUSTRIES, INC. (JP) | 2013-10-15 | — | — | US | disclosed |
| EP-2266982-B1 | ELECTRON DONATING ORGANIC MATERIAL, MATERIAL FOR PHOTOVOLTAIC ELEMENT, AND PHOTOVOLTAIC ELEMENT | TORAY INDUSTRIES (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20110023964-A1 | ELECTRON DONATING MATERIAL, MATERIAL FOR PHOTOVOLTAIC DEVICES AND PHOTOVOLTAIC DEVICE | TORAY INDUSTRIES, INC. (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2266982-A1 | ELECTRON DONATING ORGANIC MATERIAL, MATERIAL FOR PHOTOVOLTAIC ELEMENT, AND PHOTOVOLTAIC ELEMENT | Toray Industries, Inc. (JP) | 2010-12-29 | — | — | EP | disclosed |
| WO-1994002530-A1 | NOVEL PROCESSABLE THIOPHENE BASED POLYMERS AND COPOLYMERS AND THERMALLY STABLE ELECTRICALLY CONDUCTING COMPOSITIONS THEREOF | NESTE OY (FI) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229925-A1 | Process for preparing a 4,7-bis(5-halothien-2-yl)-2,1,3-benzothiadiazole and a precursor therefor | WEE2, WEE1, NOTUM | GABRA1 53/4885GABRB2 176/4885ALOX5 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.